AustriaAustria

01.02.2010

AustriaAustria

09.03.2012

Breast cancer patients who receive radiation therapy often suffer from inflammation linked to the treatment. Austrian Apeiron Biologics AG is now developing a topical superoxide dismutase treatment (APN201) to try to help these...

AustriaAustria

06.03.2012

The Paracelsus Private Medical University (PMU) in Salzburg is to build a new research center for spinal cord injuries. The €70m construction tab will be picked up by Dietrich Mateschitz, the owner of Red Bull. Other partners in...

AustriaAustria

16.12.2011

Vienna – Two big investors have poured €25m into Austrian vaccine specialist Affiris AG. Venture fund Santo VC – the investment vehicle of German biotech investors Thomas and Andreas Strüngmann – donated €20m, while the German...

AustriaAustria

08.11.2011

Vienna – In Affiris they trust – as a proof of their faith, two big investors poured €25 million into the Austrian developer of a possible Alzheimer drug. Venture fonds Santo VC, the investment vehicle of the German billionaires...

AustriaAustria

17.08.2011

Innsbruck – Austrian specialist for so-called ugimeres, Ugichem GmbH, has landed fresh funding. Along with V+ GmbH and the Austrian Research Promotion Agency, Swiss private investors invested about EUR2m to develop the first...

AustriaAustria

12.08.2011

Innsbruck – An Austrian physician has been fined EUR4,500 in a case involving a controversial stem cell therapy for incontinence. In early August, an Innsbruck Regional Court adjudged Hannes Strasser, who developed the method, at...

AustriaAustria

11.06.2011

Vienna – Nabriva Therapeutics AG, an Austrian specialist for the development of novel antibiotics, has achieved proof-of-concept for its first product in a clinical Phase II study. Called BC-3781, the compound is used to treat...

AustriaAustria

11.06.2011

Vienna – Nabriva Therapeutics AG, an Austrian specialist for the development of novel antibiotics, has achieved proof-of-concept for its first product in a clinical Phase II study. Called BC-3781, the compound is used to treat...

AustriaAustria

28.04.2011

Vienna - f-star, an antibody specialist, today announced the closing of aEUR 15 Million financing. The investment was led by SR One, the corporate venture capital arm of GlaxoSmithKline. All of f-star’s existing investors, Atlas...

Displaying results 1 to 10 out of 116

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-austria/article/-fc74978831.html

Print Magazine

Product of the week

Products

Events

All Events

Stock list

All quotes

TOP

  • FORMYCON10.43 EUR7.08%
  • EVOTEC3.27 EUR4.47%
  • MORPHOSYS78.71 EUR1.88%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • 4SC0.89 EUR-5.32%
  • CYTOS0.28 CHF-3.45%

TOP

  • CYTOS0.28 CHF75.0%
  • EPIGENOMICS5.14 EUR45.6%
  • FORMYCON10.43 EUR32.9%

FLOP

  • THERAMETRICS0.07 CHF-12.5%
  • BIOFRONTERA2.54 EUR-12.4%
  • CO.DON2.50 EUR-9.1%

TOP

  • SANTHERA92.25 CHF2738.5%
  • CO.DON2.50 EUR150.0%
  • BB BIOTECH183.00 EUR63.4%

FLOP

  • CYTOS0.28 CHF-91.7%
  • 4SC0.89 EUR-49.1%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 24.11.2014

Current issue

All issues